FDA Panel Takes ‘Leap Of Faith’ In Backing Epinephrine Nasal Spray For Anaphylaxis

 
• By Brenda Sandburg

In a split vote, advisory committee finds PK/PD data support favorable benefit-risk assessment of ARS Pharmaceuticals’ neffy, but calls for postmarket studies to evaluate its clinical efficacy.

epinephrine
FDA advisory panel finds PK/PD data supports favorable assessment of intranasal epinephrine for treatment of anaphylaxis • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers